Evaluation of dengue antiviral candidates in vivo in mouse model

Satoru Watanabe; Subhash G. Vasudevan

doi:10.1007/978-1-4939-0348-1_24

Evaluation of dengue antiviral candidates in vivo in mouse model

Satoru Watanabe
, Subhash G. Vasudevan

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

4 Citations (Scopus)

Abstract

In vivo evaluation of antiviral compounds can serve as criteria in the drug discovery process for selection of compounds that are suitable to enter late preclinical studies and further development. Dengue virus serotypes 1–4 can infect and replicate in the interferon type I and type II receptor deficient mice (AG129). Here we describe the use of a mouse-adapted dengue 2 virus strain (S221) that has been used to develop a robust lethal model of infection. Treatment with small molecule inhibitors of DENV replication at the time of infection or delayed treatment up to 48 h post infection can result in measurable protection that reflects the efficacy of the tested compound.

Original language	English
Title of host publication	Dengue
Subtitle of host publication	Methods and Protocols
Editors	Radhakrishnan Padmanabhan, Subhash G. Vasudevan
Place of Publication	New York
Publisher	Humana Press
Chapter	24
Pages	391-400
Number of pages	10
ISBN (Electronic)	9781493903481
ISBN (Print)	9781493903474
DOIs	https://doi.org/10.1007/978-1-4939-0348-1_24
Publication status	Published - 2014
Externally published	Yes

Publication series

Name	Methods in Molecular Biology
Publisher	Humana Press
ISSN (Print)	1064-3745

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

4G2 antibody
Antibody-dependent enhanced infection
Dengue antiviral testing
Dengue mouse model
Virus quantification by plaque assay

Access to Document

10.1007/978-1-4939-0348-1_24

Cite this

@inbook{2aa7d70e9fe04e889f1759cef14ac883,

title = "Evaluation of dengue antiviral candidates in vivo in mouse model",

abstract = "In vivo evaluation of antiviral compounds can serve as criteria in the drug discovery process for selection of compounds that are suitable to enter late preclinical studies and further development. Dengue virus serotypes 1–4 can infect and replicate in the interferon type I and type II receptor deficient mice (AG129). Here we describe the use of a mouse-adapted dengue 2 virus strain (S221) that has been used to develop a robust lethal model of infection. Treatment with small molecule inhibitors of DENV replication at the time of infection or delayed treatment up to 48 h post infection can result in measurable protection that reflects the efficacy of the tested compound.",

keywords = "4G2 antibody, Antibody-dependent enhanced infection, Dengue antiviral testing, Dengue mouse model, Virus quantification by plaque assay",

author = "Satoru Watanabe and Vasudevan, \{Subhash G.\}",

year = "2014",

doi = "10.1007/978-1-4939-0348-1\_24",

language = "English",

isbn = "9781493903474",

series = "Methods in Molecular Biology",

publisher = "Humana Press",

pages = "391--400",

editor = "Radhakrishnan Padmanabhan and Vasudevan, \{Subhash G.\}",

booktitle = "Dengue",

address = "United States of America",

}

Evaluation of dengue antiviral candidates in vivo in mouse model. / Watanabe, Satoru; Vasudevan, Subhash G.
Dengue: Methods and Protocols. ed. / Radhakrishnan Padmanabhan; Subhash G. Vasudevan. New York: Humana Press, 2014. p. 391-400 (Methods in Molecular Biology).

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

TY - CHAP

T1 - Evaluation of dengue antiviral candidates in vivo in mouse model

AU - Watanabe, Satoru

AU - Vasudevan, Subhash G.

PY - 2014

Y1 - 2014

N2 - In vivo evaluation of antiviral compounds can serve as criteria in the drug discovery process for selection of compounds that are suitable to enter late preclinical studies and further development. Dengue virus serotypes 1–4 can infect and replicate in the interferon type I and type II receptor deficient mice (AG129). Here we describe the use of a mouse-adapted dengue 2 virus strain (S221) that has been used to develop a robust lethal model of infection. Treatment with small molecule inhibitors of DENV replication at the time of infection or delayed treatment up to 48 h post infection can result in measurable protection that reflects the efficacy of the tested compound.

AB - In vivo evaluation of antiviral compounds can serve as criteria in the drug discovery process for selection of compounds that are suitable to enter late preclinical studies and further development. Dengue virus serotypes 1–4 can infect and replicate in the interferon type I and type II receptor deficient mice (AG129). Here we describe the use of a mouse-adapted dengue 2 virus strain (S221) that has been used to develop a robust lethal model of infection. Treatment with small molecule inhibitors of DENV replication at the time of infection or delayed treatment up to 48 h post infection can result in measurable protection that reflects the efficacy of the tested compound.

KW - 4G2 antibody

KW - Antibody-dependent enhanced infection

KW - Dengue antiviral testing

KW - Dengue mouse model

KW - Virus quantification by plaque assay

UR - https://www.scopus.com/pages/publications/84910114909

U2 - 10.1007/978-1-4939-0348-1_24

DO - 10.1007/978-1-4939-0348-1_24

M3 - Chapter (Book)

C2 - 24696350

AN - SCOPUS:84910114909

SN - 9781493903474

T3 - Methods in Molecular Biology

SP - 391

EP - 400

BT - Dengue

A2 - Padmanabhan, Radhakrishnan

A2 - Vasudevan, Subhash G.

PB - Humana Press

CY - New York

ER -

Evaluation of dengue antiviral candidates in vivo in mouse model

Abstract

Publication series

UN SDGs

Keywords

Access to Document

Other files and links

Cite this